Home > Healthcare > Immunohistochemistry Market

Immunohistochemistry Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2024 – 2032
  • Report ID: GMI5542
 Download Free Sample

Immunohistochemistry Market Size

Immunohistochemistry Market size will garner significant momentum from 2024 to 2032 owing to increased product approvals and the introduction of technologically improved devices for disease diagnosis. The rising rate of automation and machine learning implementation in immunohistochemistry (IHC) is driving the launch of various technologically advanced solutions.
 

Furthermore, the increasing technological progress is favoring the adoption of IHC for offering enhanced diagnostic capabilities, further paving the way for personalized medicine approaches. The influx of digital pathology solutions is also enabling remote access, data storage, and analysis for transforming IHC workflows. The integration of artificial AI and machine learning algorithms will streamline the result interpretation to enhance diagnostic precision. For instance, in June 2023, Aiosyn, a software firm providing AI-powered pathology solutions, launched the newest improvement in its automated quality control algorithm, which is fully compatible with IHC slides as well as hematoxylin and eosin.
 

Immunohistochemistry Market Trends

The rapid growth in companion diagnostics and the rising popularity of precision medicine is likely to foster the market expansion. IHC plays a pivotal role in companion diagnostics for enabling the identification of patients who would benefit from specific targeted therapies. The increasing adoption of personalized medicine approaches is surging the demand for IHC assays that determine the presence or absence of specific biomarkers for tailored treatment plans. Additionally, the ongoing development of targeted therapies by pharmaceutical companies will fuel the need for companion diagnostics.
 

Immunohistochemistry Market Analysis

The antibody segment may account for a significant revenue share by 2032. Antibodies are used in several applications, including pathology, neuropathology, and hematopathology, and play a critical role in disease diagnosis and drug testing. The increasing product launches by major companies are also set to fuel the segment expansion. For instance, in March 2023, Aptamer Group created a novel reagent, Optimer-Fc, for use in automated IHC.
 

The diagnosis segment is likely to record considerable progression through 2032. The increasing prevalence of various diseases, such as cancer is propelling the demand for disease diagnosis equipment. IHC assays play a pivotal role in diagnosing various diseases, including cancer, infectious diseases, and autoimmune disorders. According to the American Cancer Society, Inc., around 1.9 million new cancer cases are poised to be diagnosed in the U.S. in 2023. Moreover, advancements in IHC technologies, such as multiplex assays and digital pathology solutions to enhance diagnostic capabilities.
 

The Asia Pacific immunohistochemistry market  is anticipated to witness immense growth during 2024-2032 due to the rapidly rising rate of medical tourism. Growing collaborations between key players and research institutions are fueling technological advancements in IHC assays. The increasing implementation of new ICT standards in Japan, the rising focus on R&D investments in China, and rapid expansion of the healthcare business in India.
 

Immunohistochemistry Market Share 

Some of the prominent players in the immunohistochemistry industry are:

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Perkinelmer, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • Bio SB, Agilent Technologies, Inc.
  • Abcam plc.
     

Key immunohistochemistry firms are taking efforts to develop innovative assays, antibodies, and detection systems to sustain competitive edges. They are also focusing on expanding product portfolios, improving assay sensitivity, and offering automation solutions to reinforce their global footprint.
 

Immunohistochemistry Industry News

  • In November 2023, Biocare Medical, a renowned immunohistochemistry supplier, launched its latest breakthrough, the ARC (Antigen Retrieval Chamber) to expands its line of decloaking technologies for consistent and dependable heat-induced epitope retrieval.

 

What Information does this report contain?

Historical data coverage: 2018 to 2023; Growth Projections: 2024 to 2032.
Expert analysis: industry, governing, innovation and technological trends; factors impacting development; drawbacks, SWOT.
6-7 year performance forecasts: major segments covering applications, top products and geographies.
Competitive landscape reporting: market leaders and important players, competencies and capacities of these companies in terms of production as well as sustainability and prospects.

Frequently Asked Questions (FAQ) :

The global immunohistochemistry industry size recorded USD 2 billion in 2022 and will exhibit 6-7% CAGR from 2023 to 2032 due to growing adoption in biological research and clinical diagnostics for identifying and visualizing tissue antigens.
Antibody product segment will significantly expand through 2032 driven by rising application in pathology, neuropathology, and hematopathology, as well as disease diagnosis and drug testing.
The immunohistochemistry industry in Asia Pacific is expected to grow at a robust pace through 2032 due to the booming medical tourism sector.
Thermo Fisher Scientific Inc., Merck KGaA, F. Hoffmann-La Roche Ltd., Danaher Corporation, Perkinelmer, Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Bio SB, Agilent Technologies, Inc., and Abcam plc are some well-known immunohistochemistry market players.

Pre Book Now

 Download Free Sample